J&J Adapts Prostate Cancer Drug Dosing After Patient Deaths
Johnson & Johnson's experimental prostate cancer drug using actinium-225 showed significant tumor shrinkage in three patients but resulted in four patient deaths and five cases of interstitial lung disease, prompting plans for capped, flexible dosing.